Chemotherapy: What progress in the last 5 years?

被引:76
作者
Hamilton, A
Hortobagyi, G
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Sydney Canc Ctr, Sydney, NSW, Australia
[3] Univ Sydney, Sydney, NSW 2006, Australia
关键词
D O I
10.1200/JCO.2005.10.034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:1760 / 1775
页数:16
相关论文
共 152 条
  • [71] Hortobagyi GN, 1999, J CLIN ONCOL, V17, P25
  • [72] HORTOBAGYI GN, 2000, DIS BREAST, P645
  • [73] HORTOBAGYI GN, 2002, P AN M AM SOC CLIN, V21, P192
  • [74] HURLEY J, 2000, P AN M AM SOC CLIN, V19, pA127
  • [75] Hurley JE, 2001, BREAST CANCER RES TR, V69, P300
  • [76] Hutcheon AW, 2003, BREAST CANCER RES TR, V82, pS9
  • [77] Jackisch C, 2003, BREAST CANCER RES TR, V82, pS51
  • [78] Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer
    Jahanzeb, M
    Mortimer, JE
    Yunus, F
    Irwin, DH
    Speyer, J
    Koletsky, AJ
    Klein, P
    Sabir, T
    Kronish, L
    [J]. ONCOLOGIST, 2002, 7 (05) : 410 - 417
  • [79] RANDOMIZED COMPARISON OF VINORELBINE AND MELPHALAN IN ANTHRACYCLINE-REFRACTORY ADVANCED BREAST-CANCER
    JONES, S
    WINER, E
    VOGEL, C
    LAUFMAN, L
    HUTCHINS, L
    OROURKE, M
    LEMBERSKY, B
    BUDMAN, D
    BIGLEY, J
    HOHNEKER, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) : 2567 - 2574
  • [80] JONES S, 2004, BREAST CANC RES TREA, V82, P59